Locally advanced or metastatic non-small cell lung cancer (NSCLC)

Clinical trials for Locally advanced or metastatic non-small cell lung cancer (NSCLC) explained in plain language.

Never miss a new study

Get alerted when new Locally advanced or metastatic non-small cell lung cancer (NSCLC) trials appear

Sign up with your email to follow new studies for Locally advanced or metastatic non-small cell lung cancer (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug duo aims to tackle tough lung cancer

Disease control Recruiting now

This phase 2 trial tests a new drug called ILKN421H combined with the immunotherapy pembrolizumab in 80 people with advanced non-small cell lung cancer. The study includes patients who have already tried other treatments or are newly diagnosed with a specific biomarker. Researche…

Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

Phase 2 • Sponsor: iLeukon Therapeutics, Inc. • Aim: Disease control

Last updated Jul 12, 2026 00:00 UTC

Locally advanced or metastatic non-small cell lung cancer (NSCLC)

Get alerted when new Locally advanced or metastatic non-small cell lung cancer (NSCLC) trials appear

New drug duo aims to tackle tough lung cancer